CLEVELAND -- University Hospitals is leading an international trial investigating a first-of-its-kind on-demand drug for pre-menopausal women with sexual dysfunction.
Sheryl Kingsberg, PhD says this international Phase II study is one of the largest clinical studies to ever explore a "use-as-needed" treatment, Tefina, for women experiencing orgasmic disorder.
Tefina is a nasal gel containing testosterone and is inserted in the nose with an easy to use applicator 1-4 hours before sexual activity. The study, which will involve 240 patients in the U.S., Canada and Australia, will evaluate if there is an increase in the occurrence of orgasm over the treatment period, compared against baseline levels.
Anorgasmia, also known as female orgasmic disorder, is defined as the persistent or recurrent delay in or absence of orgasm. Although this condition affects 1 in 5 women worldwide, there are no approved treatments for anorgasmia.
Low testosterone is linked to low sexual desire and the development of climax problems. Testosterone therapy not only improves sexual desire through central actions in the brain but also results in increased vaginal blood flow, which is critical for sexual satisfaction.
Participants must be aged 18 to 49 and be unable to be sexually satisfied after previously having had no problems. For more information, call 440.995.3810.